科伦药业（002422）：创新逐步兑现，期待主业复苏

Investment Rating - The report assigns an "Accumulate" rating to Kelun Pharmaceutical [13] Core Views - The core asset SKB264 of the subsidiary has received approval for its fourth indication in China, indicating a positive outlook for the sales of innovative drugs and an expectation for the recovery of the main business [2][13] - The report anticipates total revenue for 2025-2027 to be 174.2 billion, 197.6 billion, and 225.7 billion yuan, respectively, with year-on-year growth rates of -20.1%, 13.4%, and 14.2% [13] - Expected EPS for 2025-2027 is projected to be 0.93, 1.14, and 1.72 yuan [13] - The report highlights the stable development of various business segments and the upcoming overseas launch of the first product from Kelun Botai, supporting the continued realization of the company's innovative drug business [13] Financial Summary - Total revenue for 2023 is projected at 21,454 million yuan, with a year-on-year growth of 12.7% [5] - Net profit attributable to the parent company is expected to be 2,456 million yuan in 2023, reflecting a significant increase of 44.0% [5] - The report forecasts a net profit margin of 12.3% for 2023, with a projected increase to 14.0% by 2027 [16] - The company’s total assets are estimated to reach 42,588 million yuan by 2027, with a debt-to-equity ratio of 22.9% [16] Market Data - The stock price range over the past 52 weeks is between 26.85 and 40.70 yuan, with a total market capitalization of 51,218 million yuan [8] - The report sets a target price of 45.41 yuan based on a 40x PE ratio for 2026 [13]